ARiE Trial – Rifaximin for encephalopathy
In critically ill adults with overt acute hepatic encephalopathy (HE) admitted to ICU, does the addition of rifaximin to broad spectrum antimicrobials affect time to resolution of HE?
Continue reading »A compendium of critical appraisals in Intensive Care Medicine research and related specialties
A collection of TBL summaries relevant to Intensive Care Medicine
In critically ill adults with overt acute hepatic encephalopathy (HE) admitted to ICU, does the addition of rifaximin to broad spectrum antimicrobials affect time to resolution of HE?
Continue reading »In patients with severe brain injury who require mechanical ventilation, does an early, single dose of ceftriaxone compared with placebo reduce the incidence of early VAP?
Continue reading »In patients with aneurysmal subarachnoid haemorrhage (aSAH), does lumbar CSF drainage compared to standard therapy improve clinical outcomes as measured by the modified Rankin Scale (mRS) score at 6 months?
Continue reading »In acutely ill adults (ED / ICU) does the administration of cefipime or piperacillin-tazobactam (pip-taz) result in an increased incidence of AKI or death by day 14?
Continue reading »Landiolol and Organ Failure in Patients With Septic Shock Whitehouse. JAMA Published online October 25, 2023. doi:10.1001/jama.2023.20134 Clinical Question In patients with tachycardia and septic shock who are treated with high dose norepinephrine does the use of β-blockade for up to 14 days reduce organ failure compared to standard care? Background Many view the use of β-blockade as contentious in […]
Continue reading »In trauma patients with exsanguinating haemorrhage, does the use of the REBOA (resuscitative endovascular balloon occlusion of the aorta) device with standard care in the emergency department, compared with standard care alone, impact 90-day-mortality?
Continue reading »In patients with trauma and critical bleeding who require activation of a major haemorrhage protocol, does the empiric administration of 3 pools of cryoprecipitate (6g fibrinogen) within 90 minutes of randomisation (and no more than 3 hours after injury) improve survival, compared to standard care?
Continue reading »Extracorporeal Life Support in Infarct-Related Cardiogenic Shock Thiele H. NEJM 2023; Online ahead of print. doi:10.1056/NEJMoa2307227 Clinical Question In patients presenting with acute myocardial infarction complicated by cardiogenic shock undergoing revascularisation, does the early unselected application of extracorporeal life support reduce mortality from any cause at day 30? Background The use of venoarterial extracorporeal membrane oxygenation (VA ECMO), which is […]
Continue reading »In patients with non-ST elevation out-of-hospital cardiac arrest, does expedited delivery of patients to a cardiac arrest centre, compared with delivery to the geographically closest hospital, improve all-cause mortality at 30 days?
Continue reading »In adult patients with acute decompensated heart failure (ADHF), does the addition of acetazolamide to loop diuretics improve decongestion by day 3?
Continue reading »